These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6878265)

  • 1. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism.
    Moriniere P; Roussel A; Tahiri Y; de Fremont JF; Maurel G; Jaudon MC; Gueris J; Fournier A
    Proc Eur Dial Transplant Assoc; 1983; 19():784-7. PubMed ID: 6878265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of high CaCO3 supplements on serum calcium and phosphorus in patients on regular hemodialysis treatment.
    Gonella M; Calabrese G; Vagelli G; Pratesi G; Lamon S; Talarico S
    Clin Nephrol; 1985 Sep; 24(3):147-50. PubMed ID: 4042444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients.
    Sawyer N; Noonan K; Altmann P; Marsh F; Cunningham J
    Nephrol Dial Transplant; 1989; 4(2):105-9. PubMed ID: 2496350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
    Ittel TH; Schäfer C; Schmitt H; Gladziwa U; Sieberth HG
    Klin Wochenschr; 1991 Jan; 69(2):59-67. PubMed ID: 2027271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P; Fournier A; Leflon A; Hervé M; Sebert JL; Grégoire I; Bataille P; Guéris J
    Nephron; 1985; 39(4):309-15. PubMed ID: 3982576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The control of hyperphosphataemia in haemodialysis patients.
    Papayianni L; Katopodis K; Kosmanou J; Banioti A; Katsaraki A; Palatzidou M; Prokopiou F; Betsiou V; Siamopoulos KC
    EDTNA ERCA J; 1997; 23(4):25-7. PubMed ID: 9664020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia.
    Fournier A; Moriniere P; Sebert JL; Dkhissi H; Atik A; Leflon P; Renaud H; Gueris J; Gregoire I; Idrissi A
    Kidney Int Suppl; 1986 Feb; 18():S114-9. PubMed ID: 3457987
    [No Abstract]   [Full Text] [Related]  

  • 11. Risk of orally administered aluminium hydroxide and results of withdrawal.
    Bournerias F; Monnier N; Reveillaud RJ
    Proc Eur Dial Transplant Assoc; 1983; 20():207-12. PubMed ID: 6657657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma aluminium levels in patients on maintenance haemodialysis fall when oral aluminium hydroxide is withdrawn.
    Wallace MR; Pybus J
    N Z Med J; 1983 Oct; 96(742):793-5. PubMed ID: 6578451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation.
    Morinière P; Vinatier I; Westeel PF; Cohemsolal M; Belbrik S; Abdulmassih Z; Hocine C; Marie A; Leflon P; Roche D
    Nephrol Dial Transplant; 1988; 3(5):651-6. PubMed ID: 3146723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis.
    Oe PL; Lips P; van der Meulen J; de Vries PM; van Bronswijk H; Donker AJ
    Clin Nephrol; 1987 Oct; 28(4):180-5. PubMed ID: 3690899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients.
    Jespersen B; Jensen JD; Nielsen HK; Lauridsen IN; Andersen MJ; Poulsen JH; Gammelgaard B; Pedersen EB
    Nephrol Dial Transplant; 1991; 6(2):98-104. PubMed ID: 1857534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of calcium carbonate (CaCO3) as phosphate binder in dialysis patients in long-term follow-up over 3 years].
    Sperschneider H; Günther K; Stein G; Marzoll I; Kirchner E
    Z Urol Nephrol; 1990 Aug; 83(8):449-58. PubMed ID: 2122612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hyperaluminemia in chronic hemodialysis patients. Evaluation of the respective roles of dialysate aluminum and oral aluminum hydroxide].
    Tahiri Y; Moriniere P; Jaudon MC; Dkhissi H; Rosa A; Fournier A
    Nephrologie; 1983; 4(3):129-33. PubMed ID: 6633778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium carbonate as a phosphate binder in children on continuous ambulatory peritoneal dialysis and hemodialysis.
    Sieniawska M; Roszkowska-Blaim M; Weglarska J; Jabłczyńska A; Welc-Dobies J
    Mater Med Pol; 1991; 23(3):203-8. PubMed ID: 1842716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD.
    Macia M; Coronel F; Navarro JF; Gallego E; Herrero JA; Méndez ML; Chahin J; García J
    Clin Nephrol; 1997 Sep; 48(3):181-4. PubMed ID: 9342490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.